Which has better valuation & earnings, RZLT or HCM?

HUTCHMED has higher revenue and earnings than Rezolute. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A HUTCHMED $548.51M 3.54 $456.91M N/A N/A

Is RZLT or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% HUTCHMED N/A N/A N/A

Does the media prefer RZLT or HCM?

In the previous week, HUTCHMED had 6 more articles in the media than Rezolute. MarketBeat recorded 8 mentions for HUTCHMED and 2 mentions for Rezolute. Rezolute's average media sentiment score of 0.00 beat HUTCHMED's score of -0.16 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, RZLT or ADMA?

ADMA Biologics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A ADMA Biologics $510.17M 3.84 $146.93M $0.68 12.44

Is RZLT or ADMA more profitable?

ADMA Biologics has a net margin of 32.43% compared to Rezolute's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% ADMA Biologics 32.43% 39.98% 28.08%

Does the media prefer RZLT or ADMA?

In the previous week, ADMA Biologics had 42 more articles in the media than Rezolute. MarketBeat recorded 44 mentions for ADMA Biologics and 2 mentions for Rezolute. ADMA Biologics' average media sentiment score of 0.09 beat Rezolute's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 38 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, GHRS or RZLT?

GH Research is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is GHRS or RZLT more profitable?

GH Research's return on equity of -19.36% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Rezolute N/A -58.82% -54.48%

Does the media refer more to GHRS or RZLT?

In the previous week, GH Research had 4 more articles in the media than Rezolute. MarketBeat recorded 6 mentions for GH Research and 2 mentions for Rezolute. GH Research's average media sentiment score of 0.47 beat Rezolute's score of 0.00 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OCUL or RZLT?

In the previous week, Ocular Therapeutix had 7 more articles in the media than Rezolute. MarketBeat recorded 9 mentions for Ocular Therapeutix and 2 mentions for Rezolute. Ocular Therapeutix's average media sentiment score of 0.65 beat Rezolute's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RZLT or SNDX?

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Rezolute. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 2 mentions for Rezolute. Syndax Pharmaceuticals' average media sentiment score of 1.03 beat Rezolute's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rezolute (RZLT) Competitors

$4.72 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.70 -0.02 (-0.53%)

As of 07/31/2026 07:34 PM Eastern

Compare

RZLT vs. HCM, ADMA, GHRS, OCUL, and SNDX

Should you buy Rezolute stock or one of its competitors? MarketBeat compares Rezolute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rezolute include HUTCHMED (HCM), ADMA Biologics (ADMA), GH Research (GHRS), Ocular Therapeutix (OCUL), and Syndax Pharmaceuticals (SNDX).

How does Rezolute compare to HUTCHMED?

Rezolute (NASDAQ:RZLT) and HUTCHMED (NASDAQ:HCM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Rezolute presently has a consensus price target of $9.38, suggesting a potential upside of 98.62%. HUTCHMED has a consensus price target of $14.87, suggesting a potential upside of 33.57%. Given Rezolute's stronger consensus rating and higher probable upside, equities research analysts clearly believe Rezolute is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

Rezolute has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

In the previous week, HUTCHMED had 6 more articles in the media than Rezolute. MarketBeat recorded 8 mentions for HUTCHMED and 2 mentions for Rezolute. Rezolute's average media sentiment score of 0.00 beat HUTCHMED's score of -0.16 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.0% of Rezolute shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

HUTCHMED has higher revenue and earnings than Rezolute.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
HUTCHMED	$548.51M	3.54	$456.91M	N/A	N/A

HUTCHMED's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
HUTCHMED	N/A	N/A	N/A

Summary

Rezolute beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does Rezolute compare to ADMA Biologics?

Rezolute (NASDAQ:RZLT) and ADMA Biologics (NASDAQ:ADMA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
ADMA Biologics	$510.17M	3.84	$146.93M	$0.68	12.44

In the previous week, ADMA Biologics had 42 more articles in the media than Rezolute. MarketBeat recorded 44 mentions for ADMA Biologics and 2 mentions for Rezolute. ADMA Biologics' average media sentiment score of 0.09 beat Rezolute's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	38 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

ADMA Biologics has a net margin of 32.43% compared to Rezolute's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
ADMA Biologics	32.43%	39.98%	28.08%

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 98.62%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 120.65%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ADMA Biologics beats Rezolute on 11 of the 14 factors compared between the two stocks.

How does Rezolute compare to GH Research?

GH Research (NASDAQ:GHRS) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

GH Research's return on equity of -19.36% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Rezolute	N/A	-58.82%	-54.48%

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

GH Research is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

GH Research currently has a consensus price target of $40.78, suggesting a potential upside of 45.27%. Rezolute has a consensus price target of $9.38, suggesting a potential upside of 98.62%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

56.9% of GH Research shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GH Research had 4 more articles in the media than Rezolute. MarketBeat recorded 6 mentions for GH Research and 2 mentions for Rezolute. GH Research's average media sentiment score of 0.47 beat Rezolute's score of 0.00 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GH Research beats Rezolute on 8 of the 13 factors compared between the two stocks.

How does Rezolute compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Ocular Therapeutix had 7 more articles in the media than Rezolute. MarketBeat recorded 9 mentions for Ocular Therapeutix and 2 mentions for Rezolute. Ocular Therapeutix's average media sentiment score of 0.65 beat Rezolute's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute has lower revenue, but higher earnings than Ocular Therapeutix. Rezolute is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Rezolute has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Rezolute's return on equity of -58.82% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Rezolute	N/A	-58.82%	-54.48%

Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ocular Therapeutix presently has a consensus price target of $25.11, indicating a potential upside of 207.36%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 98.62%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, research analysts plainly believe Ocular Therapeutix is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ocular Therapeutix beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Syndax Pharmaceuticals?

Rezolute (NASDAQ:RZLT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Rezolute. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 2 mentions for Rezolute. Syndax Pharmaceuticals' average media sentiment score of 1.03 beat Rezolute's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Rezolute has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Rezolute's return on equity of -58.82% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Rezolute presently has a consensus target price of $9.38, indicating a potential upside of 98.62%. Syndax Pharmaceuticals has a consensus target price of $42.55, indicating a potential upside of 123.34%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Rezolute has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Syndax Pharmaceuticals	$172.35M	9.79	-$285.42M	-$2.79	N/A

Summary

Rezolute and Syndax Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$454.50M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-5.76	7.38	282.30	24.66
Price / Sales	N/A	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	2.54	16.96	10.96	6.07
Net Income	-$74.41M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-4.45%	-1.77%	-0.64%	-0.44%
1 Month Performance	-3.87%	-8.39%	-5.23%	-4.81%
1 Year Performance	-19.59%	48.40%	61.97%	18.61%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	2.4772 of 5 stars	$4.72 flat	$9.38 +98.6%	-19.6%	$454.50M	N/A	N/A	40	Gap Up
HCM HUTCHMED	2.0805 of 5 stars	$11.12 +1.0%	$14.87 +33.7%	-35.6%	$1.92B	$548.51M	N/A	1,796	Analyst Downgrade
ADMA ADMA Biologics	4.5737 of 5 stars	$8.48 +2.5%	$18.67 +120.1%	-56.2%	$1.92B	$510.17M	12.47	530	Trending News Upcoming Earnings
GHRS GH Research	2.1795 of 5 stars	$27.75 +1.7%	$40.78 +46.9%	+104.3%	$1.90B	N/A	N/A	10	Upcoming Earnings
OCUL Ocular Therapeutix	2.7548 of 5 stars	$8.64 +1.5%	$25.11 +190.6%	-31.5%	$1.86B	$51.95M	N/A	230	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. HCM, ADMA, GHRS, OCUL, and SNDX

How does Rezolute compare to HUTCHMED?

Summary

How does Rezolute compare to ADMA Biologics?

Summary

How does Rezolute compare to GH Research?

Summary

How does Rezolute compare to Ocular Therapeutix?

Summary

How does Rezolute compare to Syndax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. HCM, ADMA, GHRS, OCUL, and SNDX

How does Rezolute compare to HUTCHMED?

Do analysts rate RZLT or HCM?

Which has more volatility and risk, RZLT or HCM?

Does the media prefer RZLT or HCM?

Do institutionals & insiders hold more shares of RZLT or HCM?

Which has better valuation & earnings, RZLT or HCM?

Is RZLT or HCM more profitable?

Summary

How does Rezolute compare to ADMA Biologics?

Do institutionals and insiders have more ownership in RZLT or ADMA?

Which has preferable earnings & valuation, RZLT or ADMA?

Does the media prefer RZLT or ADMA?

Which has more volatility & risk, RZLT or ADMA?

Is RZLT or ADMA more profitable?

Do analysts rate RZLT or ADMA?

Summary

How does Rezolute compare to GH Research?

Is GHRS or RZLT more profitable?

Which has more risk and volatility, GHRS or RZLT?

Which has higher earnings and valuation, GHRS or RZLT?

Do analysts recommend GHRS or RZLT?

Do insiders and institutionals hold more shares of GHRS or RZLT?

Does the media refer more to GHRS or RZLT?

Summary

How does Rezolute compare to Ocular Therapeutix?

Does the media refer more to OCUL or RZLT?

Which has preferable earnings and valuation, OCUL or RZLT?

Is OCUL or RZLT more profitable?

Which has more risk & volatility, OCUL or RZLT?

Do institutionals and insiders believe in OCUL or RZLT?

Do analysts recommend OCUL or RZLT?

Summary

How does Rezolute compare to Syndax Pharmaceuticals?

Do insiders and institutionals have more ownership in RZLT or SNDX?

Does the media prefer RZLT or SNDX?

Which has more volatility and risk, RZLT or SNDX?

Is RZLT or SNDX more profitable?

Do analysts prefer RZLT or SNDX?

Which has better valuation & earnings, RZLT or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools